A patient taking olaparib develops severe pancytopenia requiring transfusion. Olaparib is interrupted, but counts remain clinically abnormal after 4

Question

A patient taking olaparib develops severe pancytopenia requiring transfusion. Olaparib is interrupted, but counts remain clinically abnormal after 4 weeks and no reversible cause is found. What is the next product-information-directed step?

Accepted Answer

Bone-marrow and blood-cytogenetic assessment; discontinue olaparib if MDS or AML is confirmed

Answer

Continue observation for 12 months before investigating because MDS occurs only after treatment ends

Answer

Switch directly to niraparib without marrow assessment because MDS is specific to olaparib

Answer

Give granulocyte colony-stimulating factor and resume olaparib without evaluating persistent anaemia or thrombocytopenia

Answer

Restart olaparib at full dose because 4 weeks excludes treatment-related marrow toxicity

Ovarian Cancer — SCE Medical Oncology MCQ

A patient taking olaparib develops severe pancytopenia requiring transfusion. Olaparib is interrupted, but counts remain clinically abnormal after 4 weeks and no reversible cause is found. What is the next product-information-directed step?